NewAmsterdam Pharma Plunges 11.1% Amid Mixed Analyst Views

On April 8, 2025, NewAmsterdam Pharma's stock experienced a significant drop of 11.1% in pre-market trading, reflecting a notable decline in investor sentiment.

Analysts have expressed mixed views on the stock, with some reiterating a "buy" rating and setting a price target of $48.00, while others have given sell signals from both short and long-term moving averages, indicating a more negative outlook.

Despite the recent decline, the company has a market capitalization of $1.74 billion and a P/E ratio of -6.08, suggesting that there may be opportunities for investors who are willing to take on some risk.

Overall, the current market conditions and analyst opinions present a complex picture for NewAmsterdam Pharma, with both potential upside and downside risks to consider.